Triple drug cocktail targets tough pancreatic cancer

NCT ID NCT01204372

Completed Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of three drugs—gemcitabine, trastuzumab, and erlotinib—as a first treatment for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could control tumor growth. 63 patients received the drugs intravenously and orally until their disease worsened or side effects became too severe. The study measured how well the tumors shrank or stabilized, and how long patients lived without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemcitabine, Trastuzumab, and Erlotinib
What this could lead to: If successful, this combination could offer a new first-line treatment option to help control metastatic pancreatic cancer and extend survival.
What could go wrong: This is a small, early-phase trial with no comparison group, so results may not be definitive. The drugs can cause significant side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Centre Val d'Aurelle

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.